How Methotrexate Alters Other Drugs' Potency
Methotrexate (MTX), a folate antagonist used for rheumatoid arthritis, cancer, and psoriasis, impacts other drugs' potency mainly through enzyme inhibition and competition for transporters. It inhibits dihydrofolate reductase (DHFR) and organic anion transporters (OATs/OCTs), raising levels of co-administered drugs and risking toxicity.[1]
Key Drug Interactions Boosting Potency
- NSAIDs (e.g., ibuprofen, aspirin): MTX displaces these from protein binding sites and blocks renal secretion via OATs, doubling MTX exposure and amplifying NSAID effects like GI bleeding.[1][2]
- Probenecid: Inhibits MTX renal clearance, increasing MTX potency by 3-5 fold; used intentionally in high-dose regimens but risky otherwise.[1]
- Penicillins (e.g., piperacillin): Compete for renal secretion, elevating MTX levels up to 4-fold and intensifying side effects.[2]
- Proton pump inhibitors (PPIs, e.g., omeprazole): Reduce MTX clearance by 20-40%, heightening potency in high doses.[1][3]
Interactions Reducing Other Drugs' Potency
MTX rarely lowers potency directly but can indirectly via toxicity:
- Digoxin: MTX-induced gut toxicity decreases absorption, dropping digoxin levels by up to 30%.[2]
- Theophylline: Accelerated clearance from MTX competition reduces bronchodilator efficacy.[1]
Why Transporter Inhibition Drives Most Effects
MTX uses OAT1/3 and MRP2/4 for excretion. Co-drugs competing here (e.g., salicylates, sulfonamides) spike MTX plasma levels 2-10x, enhancing potency but causing myelosuppression or nephrotoxicity. Genetic OAT variants amplify this in 10-20% of patients.[3]
Timing and Monitoring to Manage Risks
Interactions peak 24-48 hours post-MTX dose. Low-dose weekly MTX (RA) sees milder effects than high-dose IV (cancer). Check levels, hydrate, and use leucovorin rescue. Avoid NSAIDs 48 hours around doses.[1][2]
Common Patient Scenarios and Alternatives
Rheumatoid arthritis patients on MTX + ibuprofen report 2x higher toxicity rates. Switch to acetaminophen or monitor closely. In cancer, probenecid premedication boosts MTX retention for better tumor kill but requires hospitalization.[3]
[1]: FDA Methotrexate Label
[2]: Lexicomp Drug Interactions
[3]: Clinical Pharmacology Review - MTX Transporters